Aggregation, immune complexes and immunogenicity.

Royston Jefferis

Research output: Contribution to journalArticle

25 Citations (Scopus)


The development of an immune response to a protein therapeutic may nullify its beneficial activity or result in adverse events. Immunogenicity is, therefore, a major concern for clinicians, regulatory authorities and the biopharmaceutical industry. These concerns are particularly acute for the treatment of chronic diseases, as opposed to cancer, that may require repeated exposure to therapeutic over extended cycles of remission/relapse. There are many parameters that may be contributory to immunogenicity; however, the "bête noire," for the past decade has been aggregation. ( 1-3).
Original languageEnglish
Issue number6
Publication statusPublished - 1 Nov 2011


Dive into the research topics of 'Aggregation, immune complexes and immunogenicity.'. Together they form a unique fingerprint.

Cite this